MedTrials news feed

Report Examines Cost-Effectiveness Of Larger Clinical Trials To Prevent Postapproval Adverse Events

Thu, 07 Aug 2008 20:54:55 +0100

Report Examines Cost-Effectiveness Of Larger Clinical Trials To Prevent Postapproval Adverse Events: “Use of Larger Versus Smaller Drug-Safety Databases Before Regulatory Approval: The Trade-Offs,” Health Affairs: In the Web exclusive, Shelby Reed, an associate professor of medicine at the Duke…

Cardinal Health, Inc. Profit Beats Estimates, Explores Spin-off

Thu, 07 Aug 2008 16:07:02 +0100

Cardinal Health, Inc. Profit Beats Estimates, Explores Spin-off: Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, today reported an increase in fiscal 2008 revenue of 5 percent to $91 billion and…

Genzyme And Isis Begin Second Phase 3 Trial Of Mipomersen

Thu, 07 Aug 2008 10:48:32 +0100

Genzyme And Isis Begin Second Phase 3 Trial Of Mipomersen: Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that they have begun a phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia…

Pooled-Analysis Of 54 Clinical Studies Shows No Increased Risk Of Heart Attack With Abacavir Therapy

Thu, 07 Aug 2008 10:48:32 +0100

Pooled-Analysis Of 54 Clinical Studies Shows No Increased Risk Of Heart Attack With Abacavir Therapy: GlaxoSmithKline (NYSE: GSK) (GSK) announced that a review of data from over 14,600 patients in 54 clinical studies showed no increased risk of myocardial infarction associated with the anti-HIV…

Tolerx Initiates Dosing Of Otelixizumab, A Novel Type 1 Diabetes Agent, In DEFEND, A Phase 3 Clinical Trial

Thu, 07 Aug 2008 10:48:32 +0100

Tolerx Initiates Dosing Of Otelixizumab, A Novel Type 1 Diabetes Agent, In DEFEND, A Phase 3 Clinical Trial: Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, announced the initiation of a pivotal Phase 3 clinical trial that…

SCOLR Pharma, Inc. Submits Abbreviated New Drug Application For A 12-hour CDT-based Pseudoephedrine Formulation

Thu, 07 Aug 2008 10:48:32 +0100

SCOLR Pharma, Inc. Submits Abbreviated New Drug Application For A 12-hour CDT-based Pseudoephedrine Formulation: Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that 89 percent of surveyed rheumatologists anticipate prescribing…

Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial Of Its Oral Insulin Capsule

Thu, 07 Aug 2008 09:48:32 +0100

Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial Of Its Oral Insulin Capsule: Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of oral delivery systems, announced successful results from the clinical trial of its oral insulin capsule, ORMD 0801. The trial…

Mylan Inc. Posts Loss on Acquisition Items

Thu, 07 Aug 2008 02:04:46 +0100

Mylan Inc. Posts Loss on Acquisition Items: Mylan Inc. today announced its financial results for the three and six months ended June 30, 2008.

Mylan reports loss despite much higher sales

Wed, 06 Aug 2008 18:03:25 +0100

Mylan reports loss despite much higher sales: Mylan Inc.’s 2007 purchase of Merck Generics kicked in during the drug maker’s second quarter, more than doubling revenues, but also dragging results into negative territory, the company said today.

Leukemia Journal Publishes Results From Darinaparsin Study

Wed, 06 Aug 2008 11:46:24 +0100

Leukemia Journal Publishes Results From Darinaparsin Study: ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced the publication of results from a pre-clinical study of darinaparsin (ZIO-101) in the July 17, 2008 on line advance publication issue of Leukemia, a…

Boosted Reyataz And Lopinavir/R Achieve Similar Results For Undetectable Viral Load In Treatment-Naive HIV-1 Infected Patients

Wed, 06 Aug 2008 11:46:24 +0100

Boosted Reyataz And Lopinavir/R Achieve Similar Results For Undetectable Viral Load In Treatment-Naive HIV-1 Infected Patients: Bristol-Myers Squibb Company (NYSE: BMY) announced results from a pre-specified subanalysis of the CASTLE study, in which once-daily boosted REYATAZ® (atazanavir sulfate) (REYATAZ 300 mg taken with…

Cancer Researchers And Oncologists Offer A Clinical Trial For Multiple Myeloma Patients

Wed, 06 Aug 2008 11:46:24 +0100

Cancer Researchers And Oncologists Offer A Clinical Trial For Multiple Myeloma Patients: Cancer researchers at George Mason University’s Center for Applied Proteomics and Molecular Medicine are studying the effects of experimental treatments on living tumor cells taken from multiple…

TMC278 Demonstrates Long-Term Efficacy And Tolerability In Treatment-NaÃ¯ve Adults With HIV

Wed, 06 Aug 2008 11:46:24 +0100

TMC278 Demonstrates Long-Term Efficacy And Tolerability In Treatment-NaÃ¯ve Adults With HIV: New phase IIb data from Tibotec Pharmaceuticals Ltd. show that TMC278, the company’s once-daily, investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), provides long-term efficacy…

Pharmasset Reports Preliminary Results Of A 4-week Combination Study Of R7128 For The Treatment Of Chronic Hepatitis C

Wed, 06 Aug 2008 10:46:53 +0100

Pharmasset Reports Preliminary Results Of A 4-week Combination Study Of R7128 For The Treatment Of Chronic Hepatitis C: Pharmasset, Inc. (Nasdaq: VRUS) announces the preliminary results of the third cohort of a 4-week Phase 1 clinical trial evaluating R7128 1000mg twice daily (BID) in combination with the standard of…

Tolerx Announces Achievement Of Milestones Upon Anti-CD4 Antibody Program Advancement And Initiation Of Phase 1 Clinical Trial

Wed, 06 Aug 2008 10:46:52 +0100

Tolerx Announces Achievement Of Milestones Upon Anti-CD4 Antibody Program Advancement And Initiation Of Phase 1 Clinical Trial: Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases, announced that Genentech, a collaborator, has…

Medarex Announces Allowance Of Investigational New Drug Application For Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105

Wed, 06 Aug 2008 10:46:51 +0100

Medarex Announces Allowance Of Investigational New Drug Application For Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105: Medarex, Inc. (Nasdaq: MEDX) announced the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FDA) for MDX-1105, for the treatment of patients…

Cara Therapeutics Announces Successful Completion Of Phase I Clinical Trial Of Novel Analgesic, CR845

Wed, 06 Aug 2008 10:46:49 +0100

Cara Therapeutics Announces Successful Completion Of Phase I Clinical Trial Of Novel Analgesic, CR845: Cara Therapeutics, Inc. announced completion of a Phase I clinical trial for its second-generation, peripherally acting kappa opioid agonist, CR845, under development for the treatment of acute and…

Emisphere Announces Recruitment Of Novartis Phase III Study For Oral Osteoporosis Treatment

Wed, 06 Aug 2008 10:46:47 +0100

Emisphere Announces Recruitment Of Novartis Phase III Study For Oral Osteoporosis Treatment: Emisphere Technologies, Inc. (Nasdaq: EMIS) announced that Novartis Pharma AG has finished recruitment for a multi-center Phase III study exploring the safety and efficacy of Salmon Calcitonin and…

FDA Accepts Streamlined Phase 3 Development Plan For Q8003IR 'Dual Opioid' Pain Therapy

Wed, 06 Aug 2008 10:46:43 +0100

FDA Accepts Streamlined Phase 3 Development Plan For Q8003IR 'Dual Opioid' Pain Therapy: QRxPharma Limited (ASX: QRX; OTCQX: QRXPY), a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapies for pain and central nervous system (CNS)…

Ninety-Six Week Data On Tibotec Investigational NNRTI, TMC278, Presented At AIDS 2008

Wed, 06 Aug 2008 10:46:34 +0100

Ninety-Six Week Data On Tibotec Investigational NNRTI, TMC278, Presented At AIDS 2008: New phase IIb data from Tibotec Pharmaceuticals Ltd. provides additional information on the safety and efficacy of TMC278, the company’s once-daily, investigational non-nucleoside reverse…